Immune Checkpoint Inhibitor Essentials: Key Principles, Indications, and Clinical Biomarkers

Download these slides for expert insights on key biologic principles, current indications, and clinically relevant biomarkers for immune checkpoint inhibitors.
Sandip P. Patel, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.10 MB
Released: April 16, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Bristol-Myers Squibb
Merck Sharp & Dohme Corp.

Related Content

Download slides from Clinical Care Options (CCO) in which experts provide multidisciplinary insights on the use of checkpoint inhibitors for HCC

Lipika Goyal, MD Amit G. Singal, MD, MS Released: April 30, 2021

Short slideset from a live CCO Webinar: Multidisciplinary experts on immune checkpoint inhibitor indications, biomarkers, and immune-related adverse events

Marianne Davies, DNP, CNS, ACNP-BC, AOCNP Sandip P. Patel, MD Released: April 27, 2021

Steven Waguespack, MD, on hypothyroidism after immune checkpoint inhibitors, MIBG treatment, or mitotane, and the mechanism of hyperthyroidism in cancer survivors from Clinical Care Options (CCO)

Steven G. Waguespack, MD Released: April 26, 2021

Laurie Cohen, MD, on when and how to retest for GH deficiency, how soon to start GH replacement in cancer survivors from Clinical Care Options (CCO)

Laurie E. Cohen, MD Released: April 22, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue